Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646131 | 1.00 | POLB (0.41) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14645296 | 1.00 | POLB (0.41) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14646206 | 1.00 | POLB (0.41) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14646273 | 1.00 | POLB (0.41) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL26509198 | 0.92 | DAO (0.47) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL15695246 | 0.92 | HPGD (0.43) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14646228 | 0.91 | MEN1 (0.40) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14645379 | 0.91 | KMT2A (0.35) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14645356 | 0.90 | ALDH1A1 (0.48) | POLBRAB9AMEN1KMT2AHPGDS | |
| SCHEMBL14773973 | 0.90 | DPP4 (0.37) | POLBRAB9AMEN1KMT2AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| EP-2350042-B1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPHY | CPL BCX PHARMA AB (SE) | 2015-07-29 | — | — | EP | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| WO-2010044744-A1 | NOVEL THIOPHENE COMPOUNDS FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010044743-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPHY | BIOCHROMIX PHARMA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | POLB 1618/4885RAB9A 1733/4885MEN1 2047/4885 |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | HSPE1, TTR, HTT | POLB 3105/4885RAB9A 1980/4885MEN1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.